x.com· @ · X·· 2026-04-23Score60
Body
#AACR26 spotlight: Carlota Pages-Geli, PhD, @KippWeiskopf lab, “Unbiased discovery of novel microphage-activating immunotherapies for ALK+ #NSCLC.”
💡Combining CD47 x TROP2 bispecific antibodies with lorlatinib produced synergistic anti-tumor effects.
#LungCancer https://t.co/Uqoiy10kH5
Heat 9 · 6 likes · 0 replies · 3 reposts
Conference abstracts
LB013matched by 药名 lorlatinib
Lorlatinib in advanced ALK-positive non-small cell lung cancer: Efficacy, safety and exploration of predictive biomarkers for therapeutic responseFang Wei, Linyan Tian, Huiyang Shi, Wenxin Jiang, Danru Zheng, Haiyan Xu, Yan Wang
Read the abstract →Source: x.com · x.com